PHOLCODINE cough medicines have been cancelled by the TGA and recalled from pharmacies for safety reasons.
Following a safety investigation by the TGA, 55 products containing pholcodine are being cancelled from the Australian Register of Therapeutic Goods and those currently on pharmacy shelves are being recalled from pharmacies (PD breaking news yesterday).
The recall affects a wide range of cough syrups, tablets and lozenges manufactured by Benadryl, Codral, Chemists' Own, TerryWhite, Priceline, Difflam, Bisolvon, Duro-Tuss and others.
The cancellation and recall actions are being taken because of a link between pholcodine-containing medicines and an increased risk of anaphylactic reactions (a sudden, severe and life-threatening allergic reaction) to certain medicines used as muscle relaxants during general anaesthesia (called neuromuscular blocking agents).
Pholcodine has been used in a wide range of OTC pharmacy medicines to treat non-productive (dry) cough, particularly in syrups and lozenges.
It is also used in combination with other medicines in products that treat the symptoms of cold and flu.
TGA Head Adj Prof John Skerritt said: "It is difficult to reliably predict who may be at risk of anaphylaxis during anaesthesia and some patients may not know if they have taken pholcodine medicines recently."
Skerritt explained that some patients undergoing emergency surgery may not be in a position to talk to their anaesthetist at all.
"In addition, while surgical facilities may ask about which prescription medicines a patient is taking, they may not ask about over-the-counter products."
Skerritt said that "safer alternatives to treat a dry cough are available and consumers should ask their doctor or pharmacist for advice.
"I urge consumers to check if any of your over-the-counter cold and flu medicines contain pholcodine and, if they do, ask your doctor or pharmacist to suggest an alternative treatment.
"If you will need general anaesthesia and have taken pholcodine in the past 12 months, I advise you to tell your health professional.
"Health professionals should also check whether patients scheduled to undergo general anaesthesia have used pholcodine in the previous 12 months," he said.
The TGA's investigation followed the European Medicines Agency's review recommending the withdrawal of marketing authorisations for these products in Europe.
The European findings were supported by a Western Australian study which also showed that pholcodine was a risk factor.
Up to 09 Feb, the TGA has received 50 reports of Australian cases of suspected pholcodine-related anaphylactic reactions to neuromuscular blockers, including one fatality.
The Society of Hospital Pharmacists of Australia (SHPA) Chief Executive Kristin Michaels said: "Our specialist pharmacist members working in surgical wards and medication safety services have been keenly aware of the link between pholcodine-containing medicines and an increased risk of anaphylactic reactions to neuromuscular blocking agents, which are essential to safely performing surgery.
"This specific issue has been known among clinicians for a number of years.
"Ahead of the TGA's decision, discussion by specialist pharmacists in SHPA's Medication Safety and Surgery and Perioperative Medicine streams demonstrated that hospitals across Australia were already enacting their own measures to limit the use of pholcodine."
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Mar 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Mar 23
